189 related articles for article (PubMed ID: 35953544)
1. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.
Laudanski K; Okeke T; Siddiq K; Hajj J; Restrepo M; Gullipalli D; Song WC
Sci Rep; 2022 Aug; 12(1):13658. PubMed ID: 35953544
[TBL] [Abstract][Full Text] [Related]
2. Immunological Signatures in Blood and Urine in 80 Individuals Hospitalized during the Initial Phase of COVID-19 Pandemic with Quantified Nicotine Exposure.
Laudanski K; Mahmoud MA; Ahmed AS; Susztak K; Mathew A; Chen J
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612525
[TBL] [Abstract][Full Text] [Related]
3. A decline of protective apolipoprotein J and complement factor H concomitant with increase in C5a 3 months after cardiac surgery-Evidence of long-term complement perturbations.
Laudanski K; Liu D; Gullipalli D; Song WC; Okeke T; Szeto WY
Front Cardiovasc Med; 2022; 9():983617. PubMed ID: 36606279
[TBL] [Abstract][Full Text] [Related]
4. Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients.
Barratt-Due A; Pettersen K; Børresdatter-Dahl T; Holter JC; Grønli RH; Dyrhol-Riise AM; Lerum TV; Holten AR; Tonby K; Trøseid M; Skjønsberg OH; Granerud BK; Heggelund L; Kildal AB; Schjalm C; Aaløkken TM; Aukrust P; Ueland T; Mollnes TE; Halvorsen B;
J Intern Med; 2024 Jul; 296(1):80-92. PubMed ID: 38539241
[TBL] [Abstract][Full Text] [Related]
5. Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients.
Meroni PL; Croci S; Lonati PA; Pregnolato F; Spaggiari L; Besutti G; Bonacini M; Ferrigno I; Rossi A; Hetland G; Hollan I; Cugno M; Tedesco F; Borghi MO; Salvarani C
Autoimmun Rev; 2023 Jan; 22(1):103232. PubMed ID: 36414219
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
7. C5a anaphylatoxin as a product of complement activation up-regulates the complement inhibitory factor H in rat Kupffer cells.
Schlaf G; Nitzki F; Heine I; Hardeland R; Schieferdecker HL; Götze O
Eur J Immunol; 2004 Nov; 34(11):3257-66. PubMed ID: 15376195
[TBL] [Abstract][Full Text] [Related]
8. Systemic Inflammation and Complement Activation Parameters Predict Clinical Outcome of Severe SARS-CoV-2 Infections.
Huber S; Massri M; Grasse M; Fleischer V; Kellnerová S; Harpf V; Knabl L; Knabl L; Heiner T; Kummann M; Neurauter M; Rambach G; Speth C; Würzner R
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960645
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19.
Valenti L; Griffini S; Lamorte G; Grovetti E; Uceda Renteria SC; Malvestiti F; Scudeller L; Bandera A; Peyvandi F; Prati D; Meroni P; Cugno M
J Autoimmun; 2021 Feb; 117():102595. PubMed ID: 33453462
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women.
Demers-Mathieu V; DaPra C; Medo E
Breastfeed Med; 2021 May; 16(5):393-401. PubMed ID: 33835835
[No Abstract] [Full Text] [Related]
11. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
12. Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.
Cyprian FS; Suleman M; Abdelhafez I; Doudin A; Masud Danjuma M; Mir FA; Parray A; Yousaf Z; Siddiqui MYA; Abdelmajid A; Mulhim M; Al-Shokri S; Abukhattab M; Shaheen R; Elkord E; Al-Khal AL; Elzouki AN; Girardi G
Front Immunol; 2021; 12():707159. PubMed ID: 34966381
[TBL] [Abstract][Full Text] [Related]
13. Detection of renal allograft rejection by complement components C5A and TCC in plasma and urine.
Müller TF; Kraus M; Neumann C; Lange H
J Lab Clin Med; 1997 Jan; 129(1):62-71. PubMed ID: 9011592
[TBL] [Abstract][Full Text] [Related]
14. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
15. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.
Anand SP; Prévost J; Richard J; Perreault J; Tremblay T; Drouin M; Fournier MJ; Lewin A; Bazin R; Finzi A
Transfusion; 2021 May; 61(5):1377-1382. PubMed ID: 33604922
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.
Jarlhelt I; Nielsen SK; Jahn CXH; Hansen CB; Pérez-Alós L; Rosbjerg A; Bayarri-Olmos R; Skjoedt MO; Garred P
Front Immunol; 2021; 12():767981. PubMed ID: 34804055
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
19. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.
Kowalska D; Kuźniewska A; Senent Y; Tavira B; Inogés S; López-Díaz de Cerio A; Pio R; Okrój M; Yuste JR
Front Immunol; 2022; 13():946522. PubMed ID: 36091057
[TBL] [Abstract][Full Text] [Related]
20. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge.
Senent Y; Inogés S; López-Díaz de Cerio A; Blanco A; Campo A; Carmona-Torre F; Sunsundegui P; González-Martín A; Ajona D; Okrój M; Prósper F; Pio R; Yuste JR; Tavira B
Front Immunol; 2021; 12():767376. PubMed ID: 34868021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
